Highlights Hansa Biopharma AB

Equities

HNSA

SE0002148817

Market Closed - Nasdaq Stockholm Other stock markets 11:59:36 08/05/2024 BST			5-day change	1st Jan Change
30.62 ^SEK	+5.22%		+5.81%	+16.87%

04-18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
04-18	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-18	CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue	04-12	MT
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	04-02	CI
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-02	CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-02	CI
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	01-06	CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	01-06	CI
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	12-14	CI
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	12-07	CI
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	17/10/23	MT
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant	17/10/23	CI
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial	11/10/23	CI
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients	11/10/23	CI
Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487	09/10/23	CI
Hansa Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	20/07/23	CI
Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis	19/07/23	CI
Hansa Biopharma Receives Provisional Approval in Australia for Desensitization Treatment	11/07/23	MT
Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation	11/07/23	CI
Hansa Biopharma Flags SEK1.4 Billion Write-Up Related to Idefirix	04/07/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hansa Biopharma AB

Equities

HNSA

SE0002148817

Highlights

Filters